Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia
NCT02787369Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2016
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ricolinostat in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 2 years. Started May 2016; status: active, not recruiting.
02
Drugs
ricolinostat
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02787369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787369.